Optimization of variables and assessment of in-vitro and in-vivo antihyperlipidemic activity of Eudragit RS nanoparticles containing simvastatin

扫码查看

原文链接

NETL
NSTL
万方数据

外文摘要：Simvastatin,a BCS class Ⅱ drug,is associated with poor aqueous solubility,first-pass metabolism and short half-life.In the present work,nanoparticles were prepared and evaluated.Optimization of formulation and process parameters was done through the use of independent and dependent variables.Preliminary studies were done to determine suitable range of the concentration of Eudragit polymer(10％-30％)and the ratio of drug to polymer(1:1 to 1:5)for the formation of nanoparticles by emulsification and a solvent evaporation technique.Results revealed that the mean size of nanoparticles was affected by stirring speed from 5000 RPM,8000 RPM,and 12000 RPM.The results of increase in association effi-ciency and percent yield with increase in amount of drug from 100 mg,150 mg,and 200 mg in selected range were observed.In-vitro release studies showed that two formulations possess highest initial burst and slow sustained drug release.There was 2.93-fold decrease in total cholesterol and 3.27-fold increases in triglyceride level during in-vivo study.

外文关键词：

SimvastatinEudragit RS 100NanoparticlesHyperlipidemia

作者：

Bina Gidwani、Vishal Jain、Veenu Joshi、Ravindra Kumar Pandey、Shiv Shankar Shukla、Amber Vyas

展开 >

作者单位：

Columbia Institute of Pharmacy,Raipur(C.G.),India

University Institute of Pharmacy,Pt Ravishankar Shukla University,Raipur(C.G.),India

Center for Basic Science and Research,Pt Ravishankar Shukla University,Raipur(C.G.),India

基金：

Department of Science and Technology(DST-FIST)Letter,New DelhiDepartment of Science and Technology,New Delhi,IndiaDepartment of Science and Technology,New Delhi,India

项目编号：

SR/FST/COLLEGE/2018/418DST/INSPIRE Fellowship/2019/IF190329DST/NM/NT/2018/20

出版年：

2024

DOI：

10.1016/j.partic.2023.12.006

颗粒学报(英文版)

中国颗粒学会　中国科学院过程工程研究所

颗粒学报(英文版)

CSTPCD

影响因子：0.632

ISSN：1674-2001

年,卷(期)：2024.90(7)